Pay in 4 interest-free payments of $6.32 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Indication and important safety information INCRELEX (mecasermin) is indicated for the treatment of growth failure in pediatric patients aged 2 years and older with severe primary IGF-1 deficiency* (IGFD), or with hormone (GH) gene deletion who have developed neutralizing antibodies to GH
it may an area of skin that simply looks different from that around it
Current findings remain preliminary and highlight possibilities rather than established outcomes
If this dose were to induce malaise, we would anticipate observing an acute effect of the treatment, which was not present
Third, individual variation is substantial: patients with severe insulin resistance or significant mitochondrial dysfunction may respond at lower doses than metabolically healthy athletes
